Open an account

Roivant Sciences

ROIV · NASDAQ

$34.92+$0.22 (+0.63%)TodayMarket closed ·
Prev close $34.70

About ROIV

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Employees
750
Headquarters
London
Listed
Dec 3, 2020
Sector
Health Care
Industry
Biotechnology
Website
roivant.com

ROIV key statistics

Market cap
25.22B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.72M
Volume
3.67M
Open price
$35.00
High today
$35.52
Low today
$34.38
52 Week high
$42.50
52 Week low
$17.28

Roivant Sciences (ROIV) at a glance

As of Oct 20, 2026, Roivant Sciences (ROIV) shares are priced at $34.92, giving the company a market cap of 25.22B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $34.38 and $35.52. The current price is 1.6% above the day's low and 1.7% below its high.

Volume so far is 3.67M shares, below the average of 5.72M shares a day.

Over the past year Roivant Sciences has ranged from $17.28 to $42.50, and now sits 70% of the way up that range.

Roivant Sciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY27 it reported -$0.26 per share against an estimate of -$0.336.

The average analyst price target is $49.62, 42.1% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

90%of 10 analyst ratings say Buy
  • Buy90.0%
  • Hold10.0%
  • Sell0.0%
Price target · 15 analystsAvg $49.62
Low
$36.14
Now
$34.92
High
$71.40

ROIV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 65.1% on average.

  1. Q2 FY25: reported -$0.31 per share against an estimate of -$0.2614
  2. Q3 FY25: reported $0.23 per share against an estimate of -$0.2871
  3. Q4 FY25: reported -$0.29 per share against an estimate of -$0.3142
  4. Q1 FY26: reported -$0.33 per share against an estimate of -$0.3162
  5. Q2 FY26: reported -$0.17 per share against an estimate of -$0.341
  6. Q3 FY26: reported -$0.38 per share against an estimate of -$0.324
  7. Q4 FY26: reported -$0.58 per share against an estimate of -$0.3523
  8. Q1 FY27: reported -$0.26 per share against an estimate of -$0.336

ROIV news

  • Vandana Singh

    Immunovant Ends Autoimmune Skin Disorder Program

  • Piero Cingari

    S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today

  • Avi Kapoor

    Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

  • Vandana Singh

    Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate

  • Press releaseGlobe Newswire

    Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

  • Press releaseGlobe Newswire

    Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

  • Press releaseGlobe Newswire

    Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

  • Vandana Singh

    FDA Clears First Targeted Dermatomyositis Treatment From Roivant

Similar companies

Companies in the same industry as Roivant Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.